In a patient with autosomal dominant polycystic kidney disease who needs to take fluconazole 400 mg once weekly for a fungal infection, how should tolvaptan be administered?

Tolvaptan Dosing with Concurrent Fluconazole in ADPKD

Reduce tolvaptan to half the current dose when taking fluconazole 400 mg weekly, and closely monitor for adverse effects, particularly aquaresis-related complications and liver enzyme elevations.

Drug Interaction Mechanism

Fluconazole is classified as a moderate CYP3A4 inhibitor that reduces tolvaptan clearance by 50-80%, resulting in a 200% increase in tolvaptan AUC and 80% increase in Cmax 1, 2. This substantially elevates the risk of:

• Significant diuresis and dehydration
• Acute renal failure
• Enhanced aquaretic side effects (polyuria, nocturia, polydipsia)

Specific Dosing Algorithm

If Patient is Already on Tolvaptan:

Current dose 90/30 mg:

• Reduce to 45/15 mg during fluconazole treatment
• Resume 90/30 mg one week after last fluconazole dose

Current dose 60/30 mg:

• Reduce to 30/15 mg during fluconazole treatment
• Resume 60/30 mg one week after last fluconazole dose

Current dose 45/15 mg:

• Reduce to 30 mg AM only (hold PM dose) during fluconazole treatment
• Resume 45/15 mg one week after last fluconazole dose

If Starting Tolvaptan While on Fluconazole:

• Begin with 30 mg AM only (instead of standard 45/15 mg split dosing)
• Wait at least 1 week before any dose escalation
• Monitor closely for 48-72 hours after each dose adjustment

Critical Monitoring Requirements

The KDIGO 2025 guidelines mandate specific monitoring when CYP3A inhibitors are used concurrently 3:

Enhanced surveillance during fluconazole weeks:

• Daily weight monitoring
• Serum sodium levels (morning, before tolvaptan dose)
• Fluid intake/output assessment
• Signs of volume depletion (orthostatic hypotension, dizziness, concentrated urine)

Liver function tests:

• Check AST/ALT/bilirubin before starting fluconazole if within first 18 months of tolvaptan
• Repeat LFTs if any symptoms of hepatotoxicity develop (fatigue, nausea, right upper quadrant pain, jaundice)
• Hold tolvaptan if AST/ALT ≥3× ULN or >2× baseline 3

Practical Management Considerations

Hydration strategy:

• Counsel patient to maintain aggressive fluid intake (≥3 liters/day) during fluconazole weeks
• Avoid situations with limited water access
• Monitor for hypernatremia (indicates inadequate water intake)

Timing optimization:

• Take fluconazole dose in evening to separate from morning tolvaptan dose
• This minimizes peak drug interaction effects

Common pitfall to avoid: The FDA label explicitly warns against continuing full-dose tolvaptan with moderate CYP3A inhibitors due to risk of severe diuresis and acute kidney injury 1, 2. The 50-80% reduction in tolvaptan clearance is clinically significant and cannot be ignored.

Alternative Antifungal Consideration

If the fungal infection permits, consider discussing with infectious disease whether an alternative antifungal without CYP3A4 inhibition (such as certain echinocandins or amphotericin formulations) might be appropriate, though this depends entirely on the specific fungal pathogen and infection site.

Duration of Dose Adjustment

• Maintain reduced tolvaptan dose throughout the entire fluconazole treatment period
• Continue reduced dose for 5-7 days after the last fluconazole dose (approximately 5 half-lives of fluconazole)
• Then resume previous tolvaptan dose with close monitoring for 48-72 hours

The weekly fluconazole dosing creates a recurring interaction pattern, so this dose reduction strategy must be implemented consistently each week the patient receives fluconazole 3.